Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06271252 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
A Phase 1 study of Cardiovascular Diseases and Neoplasms, sponsored by OriCell Therapeutics Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT06271252: Recruiting Phase 1 study of Cardiovascular Diseases and Neoplasms, sponsored by OriCell Therapeutics Co..
NCT06271252 is a Phase 1 study of Cardiovascular Diseases and Neoplasms that is actively recruiting participants, run by OriCell Therapeutics Co.. The registered enrollment target is 81 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06271252, a Phase 1 study of Cardiovascular Diseases and Neoplasms, is actively recruiting participants, sponsored by OriCell Therapeutics Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study
Primary Outcome
The MTD is defined as the highest dose with an observed incidence of DLT in no more than one out of six patients treated at a particular dose level.
Conditions Studied
Interventions
- DRUG OriCAR-017
Study Locations (1)
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2024-04-03 |
| Est. Completion | 2028-04-12 |
| Phase | Phase 1 |
What NCT06271252 shows while recruiting
NCT06271252 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 10 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which OriCAR-017 is the first listed.
NCT06271252 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06271252 about?
NCT06271252 is a clinical study titled "A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study". The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study
What is the current status of trial NCT06271252?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2024-04-03. Estimated completion is 2028-04-12.
What conditions does trial NCT06271252 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Neoplasms, Vascular Diseases, Hematologic Diseases, Neoplasms by Histologic Type.
What interventions are being tested in trial NCT06271252?
The interventions under investigation include: OriCAR-017 (DRUG).
Who is sponsoring clinical trial NCT06271252?
This trial is sponsored by OriCell Therapeutics Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06271252 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06271252's enrollment target sits among peer trials
81 208th of 300 higher than 93 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Prevention of Progression of Prediabetes, Obesity and CV Risk
RECRUITING · Phase 1
-
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
RECRUITING · Phase 1
-
AB-1002 in Patients With Class III Heart Failure
ACTIVE NOT RECRUITING · Phase 1
-
Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease
COMPLETED · Phase 1
-
MRI-Guided Balloon Angioplasty to Treat Blood Flow Blockage in the Legs
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI